Investors Encouraged to Participate in Regeneron Pharmaceuticals Securities Fraud Class Action Lawsuit

Opportunity for Regeneron Investors

Overview

The Schall Law Firm has issued a reminder to investors regarding a significant class action lawsuit filed against Regeneron Pharmaceuticals, Inc. This lawsuit accuses the company of violating securities laws between November 2, 2023, and October 30, 2024. Allegations include false and misleading statements made about Regeneron’s competitive practices and revenue recognition related to their popular drug, Eylea.

Background

The lawsuit is rooted in claims that Regeneron engaged in a tactics that involved paying distributors' credit card fees contingent upon them not passing those costs onto consumers. This practice effectively lowered the selling price of Eylea, misleading the market about the drug's actual sales performance and revenue generation.

This case comes under scrutiny of the Securities Exchange Act of 1934, specifically under Section 10(b) and Rule 10b-5. Investors who purchased shares during the specified timeframe are encouraged to contact Schall Law Firm to explore their legal options and rights concerning the situation.

Details on the Case

While the class of investors has not yet been certified, the Schall Law Firm is reaching out to those harmed by the alleged misconduct to ensure they understand their rights. Should any shareholder have incurred losses due to the alleged deceptive practices, now is the time to take legal action. The Schall Law Firm emphasizes that participation is vital for potential recovery.

The crux of the complaint details misrepresentations made by Regeneron regarding the Average Selling Price (ASP) of Eylea. The firm focused largely on how these practices not only affected pricing but also provided a short-term competitive edge that misled investors once the true nature of the operations came to light.

How to Participate

Investors affected by these allegations are urged to reach out to Brian Schall of the Schall Law Firm, based in Los Angeles, for a no-cost discussion about their rights. Furthermore, all communications can also be initiated through their official website or directly via email at [email protected]. The deadline to join the class action effort is March 10, 2025.

Investors should remember that by taking no action, they may remain absent class members, which could limit their ability to claim any damages or participate in the potential recovery. This is a crucial moment for those affected to leverage their rights and seek justice against the alleged securities fraud.

Conclusion

In essence, the situation highlights a critical moment for investors in Regeneron Pharmaceuticals, Inc. to take proactive steps concerning their investments. The allegations against the company have raised significant concerns, and affected shareholders are encouraged to join the class action lawsuit to seek restitution for their losses. The Schall Law Firm stands ready to guide these investors through the complexities of securities law, affirming their commitment to safeguarding shareholder rights nationwide.